Department of Transfusion Medicine, Post graduate Institute of Medical Education and Research, Chandīgarh, India.
Transfusion. 2014 May;54(5):1418-37. doi: 10.1111/trf.12421. Epub 2013 Oct 16.
Mesenchymal stem cells (MSCs) have recently generated great interest in the fields of regenerative medicine and immunotherapy due to their unique biologic properties. In this review we attempt to provide an overview of the current clinical status of MSC therapy, primarily focusing on immunomodulatory and regenerative or tissue repair applications of MSCs. In addition, current manufacturing is reviewed with attention to variation in practices (e.g., starting material, approach to culture and product testing). There is considerable variation among the 218 clinical trials assessed here; variations include proposed mechanisms of action, optimal dosing strategy, and route of administration. To ensure the greatest likelihood of success in clinical trials as the field progresses, attention must be given to the optimization of MSC culture.
间充质干细胞（MSCs）由于其独特的生物学特性，最近在再生医学和免疫治疗领域引起了极大的兴趣。在这篇综述中，我们试图概述 MSC 治疗的当前临床状况，主要关注 MSCs 的免疫调节和再生或组织修复应用。此外，还对当前的制造进行了审查，重点是实践中的差异（例如，起始材料、培养方法和产品测试）。在这里评估的 218 项临床试验中存在相当大的差异；变化包括拟议的作用机制、最佳剂量策略和给药途径。为了确保该领域进展中临床试验取得最大成功的可能性，必须注意 MSC 培养的优化。
